Kenya’s Maisha Meds Secures $5.25 Million to Extend Vital Healthcare Platform Across Africa

Maisha Meds, a prominent digital healthcare organization in Africa, has secured a substantial $5.25 million in funding for the third phase of its expansion, courtesy of the United States Agency for International Development (USAID) Development Innovation Ventures (DIV). This financial support aims to propel Maisha Meds’ efforts in broadening the reach of its mobile software platform to encompass 7,500 pharmacies and clinics across the African continent, thus making subsidized malaria care accessible to nearly one million patients.

The essence of Maisha Meds’ platform lies in its capability to connect remote pharmacists and healthcare providers with affordable, top-notch medicines while incentivizing adherence to best practices in malaria care. Furthermore, the platform extends its benefits to patients by offering discounted testing and treatment, rendering essential healthcare services more accessible and cost-effective for them.

Maisha meds

Receiving a Stage 3 grant, which represents DIV’s highest level of funding, is a testament to Maisha Meds’ capacity to expand its proven solutions that address critical global challenges. Maisha Meds initially implemented its platform in Kenya, effectively improving malaria care, and is now poised to extend its influence to other African nations.

read also Norrsken22 Debut Fund Surpasses Expectations, Secures $205M for African Tech Startups

In conjunction with the financial support from USAID DIV, Maisha Meds has also garnered backing from the Bill & Melinda Gates Foundation. These additional resources will empower Maisha Meds to broaden its reach and enhance its overall impact.

The startup was founded in 2017 and stands at the forefront of digital healthcare in Africa, dedicated to offering cost-effective, high-quality healthcare services to underserved rural communities. The organization’s mobile software platform acts as a vital link between pharmacists and clinicians, ensuring access to reasonably priced, top-quality medicines while encouraging the adoption of best practices in malaria care.

read also Liquid Intelligent Technologies Appoints Oswald Jumira as New Chief Executive Officer (CEO) for Liquid C2 Business Unit

Moreover, Maisha Meds is working diligently to expand its platform to encompass other healthcare services, including family planning and HIV prevention, further solidifying its commitment to improving the well-being of African populations.

Charles Rapulu Udoh

Charles Rapulu Udoh is a Lagos-based lawyer, who has several years of experience working in Africa’s burgeoning tech startup industry. He has closed multi-million dollar deals bordering on venture capital, private equity, intellectual property (trademark, patent or design, etc.), mergers and acquisitions, in countries such as in the Delaware, New York, UK, Singapore, British Virgin Islands, South Africa, Nigeria etc. He’s also a corporate governance and cross-border data privacy and tax expert. 
As an award-winning writer and researcher, he is passionate about telling the African startup story, and is one of the continent’s pioneers in this regard